Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

E2F3b over-expression in ovarian carcinomas and in BRCA1 haploinsufficient fallopian tube epithelium.

Smith NL, Welcsh P, Press JZ, Agnew KJ, Garcia R, Swisher EM.

Genes Chromosomes Cancer. 2012 Nov;51(11):1054-62. doi: 10.1002/gcc.21990. Epub 2012 Aug 9.

PMID:
22887716
2.

Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers.

Press JZ, Wurz K, Norquist BM, Lee MK, Pennil C, Garcia R, Welcsh P, Goff BA, Swisher EM.

Neoplasia. 2010 Dec;12(12):993-1002.

3.

Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status.

George SH, Milea A, Shaw PA.

Clin Cancer Res. 2012 Nov 15;18(22):6199-207. doi: 10.1158/1078-0432.CCR-12-2155. Epub 2012 Sep 11.

4.

The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations.

Norquist BM, Garcia RL, Allison KH, Jokinen CH, Kernochan LE, Pizzi CC, Barrow BJ, Goff BA, Swisher EM.

Cancer. 2010 Nov 15;116(22):5261-71. doi: 10.1002/cncr.25439.

5.

Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.

Staff S, Tolonen T, Laasanen SL, Mecklin JP, Isola J, Mäenpää J.

Int J Gynecol Pathol. 2014 May;33(3):309-16. doi: 10.1097/PGP.0b013e31829c673b.

PMID:
24681744
6.

Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma.

Tone AA, Begley H, Sharma M, Murphy J, Rosen B, Brown TJ, Shaw PA.

Clin Cancer Res. 2008 Jul 1;14(13):4067-78. doi: 10.1158/1078-0432.CCR-07-4959.

7.

BRCA1 and p53 protein expression in cultured ovarian surface epithelial cells derived from women with and without a BRCA1 germline mutation.

Piek JM, Dorsman JC, Massuger LF, Ansink AC, Weegenaar J, Shvarts A, Kenemans P, Verheijen RH.

Arch Gynecol Obstet. 2006 Oct;274(6):327-31. Epub 2006 Jul 7.

PMID:
16826413
8.

53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.

Pennington KP, Wickramanayake A, Norquist BM, Pennil CC, Garcia RL, Agnew KJ, Taniguchi T, Welcsh P, Swisher EM.

Gynecol Oncol. 2013 Mar;128(3):493-9. doi: 10.1016/j.ygyno.2012.12.007. Epub 2012 Dec 12.

9.

Prolonged postovulatory proinflammatory signaling in the fallopian tube epithelium may be mediated through a BRCA1/DAB2 axis.

Tone AA, Virtanen C, Shaw P, Brown TJ.

Clin Cancer Res. 2012 Aug 15;18(16):4334-44. doi: 10.1158/1078-0432.CCR-12-0199. Epub 2012 Jul 2.

10.

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.

Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, Blood KA, Smith M, Spellman PT, Wang Y, Miller DM, Horsman D, Faham M, Gilks CB, Gray J, Huntsman DG.

BMC Cancer. 2008 Jan 22;8:17. doi: 10.1186/1471-2407-8-17.

11.

BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.

McAlpine JN, Porter H, Köbel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, Huntsman DG, Gilks CB.

Mod Pathol. 2012 May;25(5):740-50. doi: 10.1038/modpathol.2011.211. Epub 2012 Jan 27.

12.

E2f3a and E2f3b make overlapping but different contributions to total E2f3 activity.

Danielian PS, Friesenhahn LB, Faust AM, West JC, Caron AM, Bronson RT, Lees JA.

Oncogene. 2008 Nov 20;27(51):6561-70. doi: 10.1038/onc.2008.253. Epub 2008 Jul 28.

13.

Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.

Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET.

J Natl Cancer Inst. 2002 Jul 3;94(13):990-1000.

14.

Promoter hypermethylation patterns in fallopian tube epithelium of BRCA1 and BRCA2 germ line mutation carriers.

Bijron JG, van der Groep P, van Dorst EB, Seeber LM, Sie-Go DM, Verheijen RH, van Diest PJ.

Endocr Relat Cancer. 2012 Feb 13;19(1):69-81. doi: 10.1530/ERC-11-0338. Print 2012 Feb.

15.

Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.

Rabban JT, Crawford B, Chen LM, Powell CB, Zaloudek CJ.

Am J Surg Pathol. 2009 Jan;33(1):111-9. doi: 10.1097/PAS.0b013e31817d74a7.

PMID:
18830124
16.

Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers.

Carcangiu ML, Radice P, Manoukian S, Spatti G, Gobbo M, Pensotti V, Crucianelli R, Pasini B.

Int J Gynecol Pathol. 2004 Jan;23(1):35-40.

PMID:
14668548
17.

Decreased progesterone receptor isoform expression in luteal phase fallopian tube epithelium and high-grade serous carcinoma.

Tone AA, Virtanen C, Shaw PA, Brown TJ.

Endocr Relat Cancer. 2011 Feb 23;18(2):221-34. doi: 10.1530/ERC-10-0235. Print 2011 Apr.

18.
19.

Inactivation of BRCA1 and BRCA2 in ovarian cancer.

Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, DeYoung B, Buller RE.

J Natl Cancer Inst. 2002 Sep 18;94(18):1396-406.

20.

Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.

Werness BA, Parvatiyar P, Ramus SJ, Whittemore AS, Garlinghouse-Jones K, Oakley-Girvan I, DiCioccio RA, Wiest J, Tsukada Y, Ponder BA, Piver MS.

J Natl Cancer Inst. 2000 Jul 5;92(13):1088-91.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk